文献速递临床血液与体液分子诊断

嗜酸性粒细胞增多症的当代分类与诊断评估

Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia.
PubMed 文献 · Am J Clin Pathol · 2020-01-01

本文综述了嗜酸性粒细胞增多症(HE)的分类与诊断评估,重点为嗜酸性肿瘤。HE病因分为原发性(肿瘤性)、继发性(反应性)和特发性三类。细胞遗传学与分子诊断进展阐明了多种肿瘤性HE的遗传基础,常见分子特征为融合基因导致异常激活的酪氨酸激酶(TK)表达。WHO认可了生物学导向的分类方案,并新建了「伴PDGFRA、PDGFRB或FGFR1重排或伴PCM1-JAK2的髓系/淋系肿瘤」这一主要疾病类别。诊断评估需结合临床、组织病理学、免疫表型分析及分子遗传学检测(包括基于二代测序的突变 panel)。原发性HE的管理主要依据 underlying 分子遗传学异常。

要点

  • HE病因分为原发性(肿瘤性)、继发性(反应性)和特发性三类。
  • WHO新建了伴PDGFRA、PDGFRB或FGFR1重排或伴PCM1-JAK2的髓系/淋系肿瘤类别。
  • 诊断需结合临床、病理、免疫表型及分子遗传学检测。

核心结论

  • 充分了解HE的最新进展对于确保及时准确的诊断及优化患者管理是必要的。

研究设计与样本

  • 本文为文献综述,并识别了示例性HE病例。

主要发现

  • HE病因多样,可分为原发性(肿瘤性)、继发性(反应性)和特发性三类。
  • 细胞遗传学和分子诊断进展阐明了多种肿瘤性嗜酸性粒细胞疾病的遗传基础。
  • 一种常见分子特征为融合基因形成,导致异常激活的酪氨酸激酶(TK)表达。
  • 其他TK基因重排及TK基因的激活体细胞突变也见于嗜酸性肿瘤。

关键数值与推荐

  • WHO认可了生物学导向的分类方案,并新建了「伴PDGFRA、PDGFRB或FGFR1重排或伴PCM1-JAK2的髓系/淋系肿瘤」这一主要疾病类别。
  • 诊断评估包括临床、组织病理学和免疫表型分析,以及分子遗传学检测(包括基于二代测序的突变 panel)。

临床怎么用

  • 原发性HE的管理主要依据 underlying 分子遗传学异常。
  • 诊断评估需综合临床、组织病理学、免疫表型及分子遗传学检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To provide an in-depth review of the classification and diagnostic evaluation of hypereosinophilia (HE), with a focus on eosinophilic neoplasms. METHODS: A review of published literature was performed, and exemplary HE cases were identified. RESULTS: Causes of HE are diverse and can be grouped under three categories: primary (neoplastic), secondary (reactive), and idiopathic. Advances in cytogenetics and molecular diagnostics have led to elucidation of the genetic basis for many neoplastic hypereosinophilic disorders. One common molecular feature is formation of a fusion gene, resulting in the expression of an aberrantly activated tyrosine kinase (TK). The World Health Organization endorsed a biologically oriented classification scheme and created a new major disease category, namely, "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2." Rearrangement of other TK genes and activating somatic mutation(s) in TK genes have also been reported in eosinophilic neoplasms. Diagnostic evaluation of HE involves a combination of clinical, histopathologic, and immunophenotypic analyses, as well as molecular genetic testing, including next-generation sequencing-based mutation panels. The management of primary HE is largely guided by the underlying molecular genetic abnormalities. CONCLUSIONS: A good knowledge of recent advances in HE is necessary to ensure prompt and accurate diagnosis, as well as to help optimize patient care.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Mattis DM, Wang SA, Lu CM, et al. Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia. Am J Clin Pathol. 2020. PMID: 32525541. doi:10.1093/ajcp/aqaa056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。